Mereo BioPharma (MREO) Leases (2022 - 2025)
Mereo BioPharma (MREO) has disclosed Leases for 4 consecutive years, with $378000.0 as the latest value for Q3 2025.
- On a quarterly basis, Leases fell 58.42% to $378000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $378000.0, a 58.42% decrease, with the full-year FY2024 number at $727000.0, down 41.61% from a year prior.
- Leases was $378000.0 for Q3 2025 at Mereo BioPharma, down from $522000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $1.7 million in Q4 2022 to a low of $378000.0 in Q3 2025.
- A 4-year average of $906888.9 and a median of $909000.0 in 2024 define the central range for Leases.
- Peak YoY movement for Leases: dropped 25.23% in 2023, then plummeted 58.42% in 2025.
- Mereo BioPharma's Leases stood at $1.7 million in 2022, then decreased by 25.23% to $1.2 million in 2023, then plummeted by 41.61% to $727000.0 in 2024, then crashed by 48.01% to $378000.0 in 2025.
- Per Business Quant, the three most recent readings for MREO's Leases are $378000.0 (Q3 2025), $522000.0 (Q2 2025), and $622000.0 (Q1 2025).